Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Regulatory product liability

GLP-1 Vision Loss Lawsuits Against Novo Lilly

Analysis based on 20 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026

Sentiment
-25
Attention
4
Articles
20
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The litigation introduces a new liability overhang for Novo Nordisk and Eli Lilly and Company, threatening the roughly $100bn annual GLP-1 market and potentially weighing on their share prices and investor confidence. Any regulatory action by the United States — Food and Drug Administration to add a NAION warning label could further dampen prescriptions and sales growth across the class.

pharmaceuticals healthcare legal services

Hundreds of patients in the United States have filed personal injury lawsuits against Novo Nordisk and Eli Lilly and Company, alleging that widely used GLP-1 medications including Ozempic, Wegovy, Mounjaro, Zepbound and Trulicity caused a rare eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which produces sudden and often permanent vision loss. Plaintiffs claim the companies knew or should have known about an increased NAION risk and failed to adequately warn patients. More than 90 lawsuits have been filed against Novo Nordisk in New Jersey state court since 2025 by patients represented by the personal-injury firm Weitz & Luxenberg, with separate cases in the US District Court for the Eastern District of Pennsylvania. Novo Nordisk calls the claims without merit and says it found no NAION safety signal in its randomized clinical trials, while Eli Lilly and Company says patient safety is its top priority and that it monitors safety reports. The United States — Food and Drug Administration has not added a NAION warning to US labels but is conducting an ongoing review through its Sentinel Initiative. The European_Medicines_Agent estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings, as did the Australia — Therapeutic Goods Administration in Australia. The American Academy of Neurology and the North American Neuro-Ophthalmology Society acknowledge reports of a possible small risk increase but stress the overall risk remains low and the evidence is mixed. The Cleveland Clinic describes NAION as rare but potentially devastating, with no established treatment to reverse the damage.

90 Novo Nordisk faced lawsuits
90 Eli Lilly and Company faced lawsuits
65 Novo Nordisk updated labels
55 Weitz & Luxenberg filed lawsuits Novo Nordisk
55 Novo Nordisk denied liability
55 Eli Lilly and Company denied liability
55 Novo Nordisk funded study
50 Karen S. Marston ordered litigation schedule
+ 7 more actions View on Dashboard
stock
Primary defendant facing more than 90 lawsuits in New Jersey state court and separate federal cases over NAION claims tied to Ozempic and Wegovy. The litigation and potential label changes pose a material liability and reputational risk to its GLP-1 franchise.
Importance 95.0 Sentiment -35.0
stock
Co-defendant in the NAION litigation involving Mounjaro, Zepbound and Trulicity. It says patient safety is its top priority and that it monitors safety reports, but the lawsuits create legal and reputational exposure for its GLP-1 portfolio.
Importance 90.0 Sentiment -30.0
govactor
US regulator that has not added a NAION warning to GLP-1 labels but is conducting an ongoing review through its Sentinel Initiative. Its eventual decision could reshape labeling and prescribing for the entire drug class.
Importance 60.0 Sentiment 0.0
govactor
Estimated NAION could affect up to one in 10,000 people with diabetes using GLP-1 medicines and required updated warnings on semaglutide product information in 2025. Its action sets a precedent that US regulators have not followed.
Importance 55.0 Sentiment 0.0
govactor
The JPML consolidated the federal vision-loss lawsuits into MDL No. 3163, centralising the litigation and potentially streamlining its resolution.
Importance 50.0 Sentiment 0.0
cnt
Jurisdiction where hundreds of patients have sued the GLP-1 drugmakers and where the United States — Food and Drug Administration has so far declined to add a NAION warning label, unlike regulators abroad.
Importance 50.0 Sentiment 0.0
priv
US personal-injury law firm representing patients in more than 90 lawsuits filed against Novo Nordisk in New Jersey state court since 2025, driving the litigation against the GLP-1 makers.
Importance 45.0 Sentiment 0.0
govactor
The UK MHRA updated its guidance in February 2026 to include NAION as a very rare side effect of semaglutide and advised discontinuation if confirmed, adding to the regulatory pressure on the drugmakers.
Importance 40.0 Sentiment 0.0
per
Judge Karen S. Marston is overseeing the federal MDL and has ordered early resolution of key issues, shaping the course of the litigation.
Importance 40.0 Sentiment 0.0
govactor
Australian regulator that required drugmakers to include warnings about a potentially increased NAION risk with certain GLP-1 medicines, adding to the global regulatory pressure on the drugmakers.
Importance 40.0 Sentiment 0.0
cnt
Denmark, home to Novo Nordisk, saw its Patient Compensation association award compensation to four patients who lost vision after taking Wegovy or Ozempic, highlighting international legal exposure.
Importance 30.0 Sentiment 0.0
per
Dr Joseph F. Rizzo III authored a 2024 study linking semaglutide to increased NAION risk, providing a scientific basis for the lawsuits, though he has cautioned against stopping medication based on his findings.
Importance 30.0 Sentiment 0.0
alliance
Its European Union — European Medicines Agency required updated warning labels noting the possible NAION risk for semaglutide products, contrasting with the US position and pressuring the drugmakers globally.
Importance 30.0 Sentiment 0.0
ngo
Medical body that acknowledges reports of a possible small increase in NAION risk but says other studies found no correlation and the overall risk remains low, tempering the alarm around the litigation.
Importance 30.0 Sentiment 0.0
ngo
Specialist society that acknowledges reports suggesting a possible small NAION risk increase while stressing that other studies found no correlation and overall risk remains low.
Importance 25.0 Sentiment 0.0
+ 12 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.